Genzyme Corp. is expanding a deal designed to transfer more so-called fill-finish manufacturing work to Hospira Worldwide Inc. The transfer of this work is part of an agreement with the U.S. Food and Drug Administration to comply with an enforcement action against the Cambridge-based biotechnology company.
The amended deal covers three new marketed Genzyme products: Campath, Thymoglobulin and Lumizyme, in addition to some pre-approval products currently in development. Hospira already provides fill-finish work, which includes packaging and labeling, for Cerezyme, Fabrazyme, Myozyme and Thyrogen - four products that are produced at the Allston plant that is the subject of the FDA enforcement action. The plant was closed for six weeks last summer, prompting shortages of two drugs to treat rare diseases.
Under the agreement, Genzyme will be required to purchase minimum quantities of filled and finished products based on its forecasted supply requirements. The financial terms of the agreement were not disclosed.
“We’re pleased to expand our relationship with Genzyme,” Hospira spokesman Dan Rosenberg said Thursday.